Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
NCT05638295
Recruiting
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Pan... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Swedish Medical Center-First Hill, Seattle, Washington
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
NCT05630066
Recruiting
This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (inclusive) will be enrolled in the study.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/21/2024
Locations: Multicare Institute for Research and Innovation, Tacoma, Washington
Conditions: Angelman Syndrome
Register for Updates
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT05620823
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Investigative Site US308, Spokane, Washington
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
NCT05574101
Recruiting
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Washington (Data Collection Only), Seattle, Washington
Conditions: Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
Register for Updates
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377
Recruiting
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests loo... Read More
Gender:
All
Ages:
All
Trial Updated:
06/21/2024
Locations: Swedish Cancer Institute-Edmonds, Edmonds, Washington
Conditions: Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Register for Updates
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297
Recruiting
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. Cohort A: Participants with relapsed or refractory MCL rel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Medical Oncology Associates, PS ( Site 0005), Spokane, Washington
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Register for Updates
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325
Recruiting
The study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic short stature. The purpose of the study is to see how well treatment with somapacitan works compared to treatment with Norditropin®. Somapacitan is a new medicine, and Norditropin® is a medicine doctors can already prescribe in some countries. The study will last for about 3 years. The participants will either get somapacitan once a week for 3 years or... Read More
Gender:
All
Ages:
Between 2 years and 10 years
Trial Updated:
06/21/2024
Locations: MultiCare Inst for Res & Innov, Tacoma, Washington
Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS
Register for Updates
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
NCT05308446
Recruiting
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Swedish Cancer Institute-Edmonds, Edmonds, Washington
Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Register for Updates
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225
Recruiting
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 recept... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Swedish Cancer Institute-Edmonds, Edmonds, Washington
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma
Register for Updates
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT05232929
Recruiting
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study,... Read More
Gender:
All
Ages:
All
Trial Updated:
06/21/2024
Locations: MultiCare Health System Institute for Research and Innovation, Tacoma, Washington
Conditions: Spinal Muscular Atrophy
Register for Updates
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Gl... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
06/21/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Malignant Glioma, Anaplastic Astrocytoma, Not Otherwise Specified, Glioblastoma, Not Otherwise Specified
Register for Updates
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
NCT04910269
Recruiting
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that asse... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Swedish Hospital First Hill, Seattle, Washington
Conditions: COVID, SARS-CoV2 Infection, Covid19
Register for Updates